References - Therapeutic Strategies in Cancer Biology and Pathology - page 254

Umetani, N., Mori, T., Koyanagi, K., Shinozaki, M., Kim, J., Giuliano, A.E., et al. 2005.
Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node
metastasis in T1 breast cancer. Oncogene 24, 4721-4727.
Ungefroren, H., Sebens, S., Groth, S., Gieseler, F., Faendrich, F., 2011. The Src Family kinase
inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and dif-
ferential inhibition of type I and type II TGF-beta receptors. Curr. Cancer Drug Targets
11, 524-535.
Unoki, M., Nakamura, Y., 2001. Growth-suppressive effects of BPOZ and EGR2, two genes
involved in the PTEN signaling pathway. Oncogene 20, 4457-4465.
Unoki, M., Kumamoto, K., Harris, C.C., 2009. ING proteins as potential anticancer drug tar-
gets. Curr. Drug Targets 10, 442-454.
Urbich, C., Kuehbacher, A., Dimmeler, S., 2008. Role of microRNAs in vascular diseases,
inflammation, and angiogenesis. Cardiovasc. Res. 79, 581-588.
Urtasun, R., Latasa, M.U., Demartis, M.I., Balzani, S., Goni, S., Garcia-Irigoyen, O., et al.,
2011. Connective tissue growth factor autocriny in human hepatocellular carcinoma:
oncogenic role and regulation by epidermal growth factor receptor/Yes-associated pro-
tein-mediated activation. Hepatology 54, 2149-2158.
Valencia-Sanchez, M.A., Liu, J., Hannon, G.J., Parker, R., 2006. Control of translation and
mRNA degradation by miRNAs and siRNAs. Genes. Dev. 20, 515-524.
Van der Weyden, L., Adams, D.J., 2007. The Ras-association domain family (RASSF) mem-
bers and their role in tumorigenesis. Biochim. Biophys. Acta 1776, 58-85.
Van Dieck, J., Fernandez-Fernandez, M.R., Veprintsev, D.B., Fersht, A.R., 2009. Modulation
of the oligomerization state of p53 by differential binding of proteins of the S100 family
to p53 monomers and tetramers. J. Biol. Chem. 284, 13804-13811.
Van Dieck, J., Brandt, T., Teufel, D.P., Veprintsev, D.B., Joerger, A.C., Fersht, A.R., 2010.
Molecular basis of S100 proteins interacting with the p53 homologs p63 and p73.
Oncogene 29, 2024-2035.
Van Jaarsveld, M.T.M., Helleman, J., Berns EMJJ, Wiemer E.A.C., 2010. MicroRNAs in ovar-
ian cancer biology and therapy resistance. Int. J. Biochem. Cell. Biol. 42, 1282-1290.
Varelas, X., Samavarchi-Tehrani, P., Narimatsu, M., Weiss, A., Cockburn, K., Larsen, B.G.,
et al., 2010. The Crumbs complex couples cell density sensing to Hippo-dependent con-
trol of the TGF-beta-SMAD pathway. Develop. Cell 19, 831-844.
Vazques-Martin, A., Oliveras-Ferraros, C., Menendez, J.A., 2009. The antidiabetic drug
metformin suppresses HER2 (erbB2) oncoprotein over expression via inhibition of the
mTOR effector p70S6K1 human breast carcinoma cells. Cell Cycle 8, 88-96.
Vazquez-Martin, A., Oliveras-Ferraros, C., Cufi, S., Del Barco, S., Martin-Castillo, B., Lopez-
Bonet, E., et al., 2011. The anti-diabetic drug metformin suppresses the metastasis-associated
protein CD24 in MDA-MB-468 triple-negative breast cancer cells. Oncol. Rep. 25, 135-140.
Vazquez-Martin, A., Vellon, L., Quiros, P.M., Cufi, S., de Galarreta, E.R., Oliveras-Ferraros,
C., et al., 2012. Activation of AMP-activated protein kinase (AMPK) provides a meta-
bolic barrier to reprogramming somatic cells into stem cells. Cell Cycle 11, 974-989.
Veerapandiyan, A., Abdul-Rahman, O.A., Adam, M.P., Lyons, M.J., Manning, M., Coleman,
K., et al., 2011. Chromosome 22q11.2 deletion syndrome in African-American patients:
a diagnostic challenge. Am. J. Med. Genet. 155A, 2186-2195.
Vega, M.I., Martinez-Paniagua, M., Huerta-Yepez, S., Gonzalez-Bonilla, C., Uematsu, N.,
Bonavida, B., 2009. Dysregulation of the cell survival/anti-apoptotic NF-kappa B path-
way by the novel humanized BM-ca anti-CD20 mAb: implication in chemosensitization.
Int. J. Oncol. 35, 1289-1296.